Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

Roach, Mack; Lu, Jiandong; Pilepich, Miljenko V.; Asbell, Sucha O.; Mohuidden, Mohammed; Terry, Roger; Grignon, David J.; Lawton, Colleen A.; Shipley, William U.; Cox, James D.

doi:10.1016/s0360-3016(00)00577-0

Cited by 163 publications

(53 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contrary to the observation published for exclusive EBRT of 70-72 Gy [34], a short course of neoadjuvant androgen deprivation therapy did not change the bned rates in the present work. Similar conclusions have been reported when particularly high radiation doses are delivered [11,25].…”

Section: Discussioncontrasting

confidence: 99%

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Nickers¹,

Coppens

Leval

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

Background and purpose: To evaluate on 201 locally advanced prostatic cancers prospectively treated in a phase II trial, the efficacy of a combination of external beam radiotherapy (39.6 Gy) and 192 Ir low dose rate brachytherapy (Bt) (40-45 Gy).Patients and methods: Sixty-four patients were included in the intermediate prognosis group with only one of the following adverse factors (PSAO10 ng/ml, Gleason scoreR7 or clinical stageRT2b) and 137 in the unfavourable group when at least two of these factors were present.Results: The actuarial 4 years biochemical no evidence of disease is 82.8% for the entire population. It is, respectively, 97 and 76% in the intermediate and unfavourable prognosis groups (P!0.0001). GradeR3 late urinary complications occurred in 13 patients (6.5%). Eight patients (4%) presented late grade 2 rectal complications but no grades 3-5 was observed.Conclusions: Even if an a/b of 1.5-3 Gy theoretically favours the use of a high dose rate mode of irradiation, the early results presented here are as good as those reported for similar groups of patients with high dose rate treatments. Late toxicity is identical but our urinary toxicity is within the less favourable and rectal toxicity within the most favourable results.We can postulate that while inducing very high hyperdosage regions (V150) mainly focused on the peripheral zone, most of the Bt techniques consist of a more ablative treatment. Many of the radiobiological studies on Bt did not in fact take into account the heterogeneity of irradiation inside the CTV. This study highlights the need to explore pulsed dose rate therapies, permanent implant and new available radioisotopes such as 169 Ytterbium that will offer the safety of low and lower dose rates. The actual late toxicity of the different Bt techniques is not yet inexistent indeed. q

show abstract

Section: Discussioncontrasting

confidence: 99%

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Nickers¹,

Coppens

Leval

et al. 2006

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…30 Four reviews of AHT were found, one of which was a systematic review and has therefore been included here. 31 One clinical trial was found (evidence level 1) comparing hormonal therapy before, during and after EBRT versus EBRT alone (n = 120). 13 There were two retrospective matched case-control studies (evidence level 3).…”

Section: Ahtmentioning

confidence: 99%

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

Hummel

Paisley²,

Morgan³

et al. 2003

Health Technol Assess

107

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. The editors and publisher have tried to ensure the accuracy of this report but do not accept liability for damages or losses arising from material published in this report. HTAISSN 1366-5278 © Queen's Printer and Controller of HMSO 2003This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.Applications for commercial reproduction should be addressed to HMSO,The Copyright Unit, St Clements House, 2-16 Colegate, Norwich, NR3 1BQ.Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

“…Patients in risk group 2 (either GS 2 -6 with bulky tumours, or GS 7 with organ-confined disease) benefited from 4 months of flutamide and goserlin. Patients in risk groups 3 and 4 (T3 GS 7 or GS 8 -10) benefited from long-term hormonal therapy (Roach et al, 2000b).…”

Section: Rtog Meta-analysismentioning

confidence: 99%

The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials

Gottschalk

Roach

2004

Br J Cancer

View full text Add to dashboard Cite

In 1901, Wilhelm Conrad Rö ntgen won the Nobel prize in Physics for his discovery of the Rö ntgen rays or, as he himself called them, X-rays. In 1966, Dr Charles Brenton Higgins won the Nobel Prize in Medicine for his breakthroughs concerning hormonal treatment of prostatic cancer. After 31 years, in 1997, the first prospective randomised trials of the combination of hormonal therapy and radiation therapy were published, showing increased survival when compared to radiation therapy alone for patients with prostate cancer. Since 1997, many investigators have published trials combining hormonal and radiation therapy for prostate cancer. This minireview will address the largest and most influential of these trials, and attempt to guide physicians in selecting the appropriate patients for this combined approach.

show abstract

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

Cited by 163 publications

References 19 publications

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: A phase II trial

Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review

The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials

Contact Info

Product

Resources

About